Actr707 t-cells - a preparation of autologous t-lymphocytes that have been genetically modified, using proprietary antibody-coupled t-cell receptor (actr) technology, to express a chimeric protein containing, at least, the extracellular fc receptor domain of cd16, normally found on certain immune cells, such as natural killer (nk) cells, coupled to the co-stimulatory signaling domain of cd28, with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient with co-administration of a cancer-specific antibody, the co-administered antibody targets and binds to the tumor-associated antigen (taa) expressed on the tumor cell. In turn, the autologous actr-cd16-cd28-expressing t-lymphocytes actr707 bind to the antibody, become activated and induce the destruction of the tumor cells by a) releasing cytotoxins that directly kill cancer cells; b) releasing cytokines that trigger an immune response and recruit other immune-mediated killer cells to kill the tumor cells; c) targeting and killing adjacent tumor cells that are not bound to the antibody; d) inducing t-cell proliferation and thereby further enhancing the t-cell mediated tumor cell attack. Compared to other t-cell products, actr-based products do not target a specific taa and can potentially be used in a variety of tumors because targeting is based on the specificity of the co-administered antibody. Also see autologous actr-cd16-cd28-expressing t-lymphocytes actr707
Up to date info
Latest research - Actr707 t-cells
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Actr707 t-cells for any updates.